Locally administered kudzuvine root related pharmaceutical composition

A technology for topical administration and composition, which is applied to the field of pueraria-related pharmaceutical compositions for topical administration, and can solve the problems of death, inability to administer medication in an amount, and inability to strictly follow doctor's orders to administer medication.

Pending Publication Date: 2021-06-11
刘力
View PDF10 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, this treatment modality poses some difficulties, such as having to give one drug, wait a few minutes, and then give the second drug
Also, since brimonidine needs to be dosed three times a day while puerarin only needs to be taken twice, this may cause some additional difficulties for the patient, either remembering a single brimonidine dose or administering puerarin by chance
In the long-term medication process, there will be problems with the compliance of the treatment medication. Once the patient has this problem, the intraocular pressure may suddenly rise due to the inability or inaccuracy of the medication or the interruption of the treatment, resulting in head or Physical discomfort or serious consequences, or severe b

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Locally administered kudzuvine root related pharmaceutical composition
  • Locally administered kudzuvine root related pharmaceutical composition
  • Locally administered kudzuvine root related pharmaceutical composition

Examples

Experimental program
Comparison scheme
Effect test

preparation example Construction

[0103] In the preparation process of each embodiment of the present invention, in the case where the prescription of the embodiment has defined the names of the components, for the sake of simplicity, the names of the components in the prescription can be simplified or omitted. For example, "puerarin monohydrate", "edetate disodium dihydrate", etc., after the prescription components appear, they can be referred to simply as "puerarin", "edetate disodium" and so on.

[0104] Concentration units used in the description of the present invention have molar concentration (M) or (mol / L) or equivalent concentration (N), or percentage concentration etc., time unit can use second (s), minute (min), hour (h) Etc., volume unit can use liter (l or L), milliliter (ml), microliter (μl), mass unit can use gram (g), milligram (mg) and so on.

[0105] "Appropriate amount of water for injection", "appropriate amount of sodium chloride", etc. all refer to the appropriate less or minimum amount o...

Embodiment 1

[0109] The preparation of embodiment 1 compound brimonidine tartrate gel eye drops in situ

[0110] Prescription: brimonidine tartrate 0.5g, puerarin monohydrate 10g, poloxamer 188 50g, polyethylene glycol 4005g, trehalose 10g, disodium hydrogen phosphate heptahydrate 4g, methionine 3g, edetate di Sodium 0.3g, 2M citric acid solution and 2M sodium hydroxide solution are appropriate, and the volume of water for injection is adjusted to 1000ml.

[0111] Preparation process: Weigh the prescribed amount of Poloxamer 188, place it in a beaker of 700ml water for injection, stir to dissolve, and take the prescribed amount of polyethylene glycol 400, brimonidine tartrate, puerarin monohydrate, and methionine respectively , trehalose, and disodium hydrogen phosphate heptahydrate in a beaker of 200ml water for injection, stir to dissolve, mix the two solutions, adjust the pH value of the solution to 6.8 with an appropriate amount of citric acid solution and sodium hydroxide solution, ad...

Embodiment 2

[0112] The preparation of embodiment 2 compound recipe brimonidine tartrate gel eye drops

[0113] Prescription: L-brimonidine tartrate 2g, puerarin monohydrate 2.5g, carbomer 940 6g, polyvinyl alcohol 2g, trehalose 3g, taurine 5g, benzalkonium bromide 0.01g, edetate di Sodium dihydrate 0.3g, Tween-80 1g, appropriate amount of 2M citric acid solution and 2M sodium hydroxide solution, and dilute to 1000g with water for injection.

[0114] Preparation process: Take the prescribed amount of Carbomer 940 and polyvinyl alcohol in a beaker, add about 850ml of water, let it stand still to make it swell, adjust the pH value to neutral with 2M citric acid solution and 2M sodium hydroxide, and obtain the matrix. Separately take edetate disodium dihydrate, brimonidine tartrate, puerarin monohydrate, trehalose, taurine, benzalkonium bromide, Tween-80, add water and stir to make them miscible, slowly add to In the above matrix, stir evenly, add water to 1000g, vacuum degas, pack in 10g tu...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention provides preparation of an effective dose of puerarin or pharmaceutically acceptable salts thereof and the like and an effective dose of brimonidine or pharmaceutically acceptable salts thereof or/and an effective dose of anti-xerophthalmia pharmaceutical composition. The invention also relates to an application of the compound in preparation of ophthalmic medicines for preventing or treating intraocular pressure of human or mammals or treating intraocular pressure rise, glaucoma, fundus diseases, xerophthalmia or dry eye diseases or dry eye syndromes, and local medicines for acne rosacea, erythema rosacea and the like. The medicine provided by the invention has better curative effect or lower side effect or better treatment compliance or better treatment mode.

Description

technical field [0001] The present invention relates to the technical field of medicine, in particular provides effective doses of brimonidine for the prevention or treatment of increased intraocular pressure, glaucoma, fundus diseases, such as retinal arteriovenous occlusion, optic atrophy, inflammatory skin diseases, etc. The pharmaceutical composition and application of puerarin or its pharmaceutically acceptable salt and effective dosage of puerarin or its pharmaceutically acceptable salt or its solvate or hydrate. Background technique [0002] Glaucoma (glaucoma) is a group of optic nerve diseases, including the loss of retinal ganglion cells. It is the second most blind eye disease in the world. If it is not treated in time, it will cause visual field defect or complete loss, leading to blindness. It is the most important cause of irreversible blindness. reason. The onset of glaucoma is rapid and harmful. Increased pathological intraocular pressure (IOP) is the most i...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/352A61K31/498A61K31/737A61K31/4725A61K31/7072A61K9/00A61K9/08A61K9/06A61K47/69A61P27/06A61P27/02A61P9/10A61P29/00A61P17/00A61P17/10A61P17/06A61P39/06A61P7/04
CPCA61K31/352A61K31/498A61K31/737A61K31/4725A61K31/7072A61K9/0048A61K9/08A61K9/06A61K47/26A61K47/6951A61P27/06A61P27/02A61P9/10A61P29/00A61P17/00A61P17/10A61P17/06A61P39/06A61P7/04A61K2300/00
Inventor 刘力
Owner 刘力
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap